Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
May 12, 2015: JAMA
#22
JOURNAL ARTICLE
Kunj Gohil
Nivolumab (Opdivo) for unresectable or metastatic melanoma; ombitasvir/paritaprevir/ritonavir with dasabuvir (Viekira Pak) for hepatitis C virus infection; and olaparib (Lynparza) for ovarian cancer.
March 2015: P & T: a Peer-reviewed Journal for Formulary Management
#23
JOURNAL ARTICLE
David B Rein, John S Wittenborn, Bryce D Smith, Danielle K Liffmann, John W Ward
BACKGROUND: New hepatitis C virus (HCV) treatments deliver higher cure rates with fewer contraindications, increasing demand for treatment and healthcare costs. The cost-effectiveness of new treatments is unknown. METHODS: We conducted a microsimulation of guideline testing followed by alternative treatment regimens for HCV among the US population aged 20 and older to estimate cases identified, treated, sustained viral response, deaths, medical costs, quality-adjusted life-years (QALYs), and the incremental cost-effectiveness ratio (ICER) of different treatment options expressed as discounted lifetime costs and benefits from the healthcare perspective...
July 15, 2015: Clinical Infectious Diseases
#24
REVIEW
(no author information available yet)
No abstract text is available yet for this article.
February 2, 2015: Medical Letter on Drugs and Therapeutics
1
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
